STCube

STCube Forward P/E

The Forward P/E Ratio of STCube (052020.KQ) as of Oct 24, 2026 is -50.79. In the previous year, Forward P/E Ratio was -51.66 — a change of -1.67% (higher).

Forward P/E

-50.79

YoY

-1.67%

Last updated:

Forward P/E Ratio of STCube is 2025 -50.79 . Forward P/E Ratio of STCube was 2024 -51.66 . It decreases by -1.67% higher compared to the previous year.

The STCube Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-103.42 KRW
Jan 1, 2019
-91.91 KRW
Jan 1, 2020
-69.42 KRW
Jan 1, 2021
-51.43 KRW
Jan 1, 2022
-58.61 KRW
Jan 1, 2023
-45.20 KRW
Jan 1, 2024
-51.66 KRW
Jan 1, 2025
-50.79 KRW
The STCube Forward P/E history
YEARForward P/EYoY
-50.79-1.67%
-51.66+14.29%
-45.20-22.89%
-58.61+13.96%
-51.43-25.92%
-69.42-24.47%
-91.91-11.13%
-103.42+53.67%
-67.30-61.91%
-176.68-12.20%
-201.23—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Forward P/E Ratio of STCube is -50.79 in 2025.

Forward P/E Ratio of STCube changed from -51.66 to -50.79, representing a -1.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio STCube since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's STCube with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — STCube

All Key Metrics — STCube